Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more
Shenzhen Neptunus Bioengineering Co Ltd (000078) - Total Assets
Latest total assets as of September 2025: CN¥27.28 Billion CNY
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) holds total assets worth CN¥27.28 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Neptunus Bioengineering Co Ltd - Total Assets Trend (1995–2024)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shenzhen Neptunus Bioengineering Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Neptunus Bioengineering Co Ltd's total assets of CN¥27.28 Billion consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.0% |
| Accounts Receivable | CN¥18.21 Billion | 63.2% |
| Inventory | CN¥3.49 Billion | 12.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥470.26 Million | 1.6% |
| Goodwill | CN¥378.70 Million | 1.3% |
Asset Composition Trend (1995–2024)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Neptunus Bioengineering Co Ltd's current assets represent 89.7% of total assets in 2024, an increase from 57.4% in 1995.
- Cash Position: Cash and equivalents constituted 12.0% of total assets in 2024, down from 13.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 18.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 63.2% of total assets.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Neptunus Bioengineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩202.42 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Shenzhen Neptunus Bioengineering Co Ltd generates 1.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shenzhen Neptunus Bioengineering Co Ltd is currently not profitable relative to its asset base.
Shenzhen Neptunus Bioengineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 1.04 | 1.06 |
| Quick Ratio | 0.89 | 0.91 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥640.63 Million | CN¥ 1.16 Billion | CN¥ 1.76 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Neptunus Bioengineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -10.9% |
| Total Assets | CN¥28.80 Billion |
| Market Capitalization | $616.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Neptunus Bioengineering Co Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shenzhen Neptunus Bioengineering Co Ltd's assets decreased by 10.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2024)
The table below shows the annual total assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥28.80 Billion | -10.85% |
| 2023-12-31 | CN¥32.30 Billion | -10.89% |
| 2022-12-31 | CN¥36.25 Billion | -3.59% |
| 2021-12-31 | CN¥37.60 Billion | -5.33% |
| 2020-12-31 | CN¥39.72 Billion | -3.52% |
| 2019-12-31 | CN¥41.17 Billion | +0.10% |
| 2018-12-31 | CN¥41.13 Billion | +33.25% |
| 2017-12-31 | CN¥30.86 Billion | +85.24% |
| 2016-12-31 | CN¥16.66 Billion | +30.55% |
| 2015-12-31 | CN¥12.76 Billion | +32.50% |
| 2014-12-31 | CN¥9.63 Billion | +20.11% |
| 2013-12-31 | CN¥8.02 Billion | +36.77% |
| 2012-12-31 | CN¥5.86 Billion | +21.26% |
| 2011-12-31 | CN¥4.84 Billion | +16.58% |
| 2010-12-31 | CN¥4.15 Billion | +31.06% |
| 2009-12-31 | CN¥3.16 Billion | +13.94% |
| 2008-12-31 | CN¥2.78 Billion | -11.02% |
| 2007-12-31 | CN¥3.12 Billion | -11.38% |
| 2006-12-31 | CN¥3.52 Billion | -11.63% |
| 2005-12-31 | CN¥3.99 Billion | +6.93% |
| 2004-12-31 | CN¥3.73 Billion | -7.49% |
| 2003-12-31 | CN¥4.03 Billion | +17.50% |
| 2002-12-31 | CN¥3.43 Billion | +12.67% |
| 2001-12-31 | CN¥3.04 Billion | +248.92% |
| 2000-12-31 | CN¥872.30 Million | +35.81% |
| 1999-12-31 | CN¥642.28 Million | +179.29% |
| 1998-12-31 | CN¥229.97 Million | +57.92% |
| 1997-12-31 | CN¥145.63 Million | +18.39% |
| 1996-12-31 | CN¥123.00 Million | +49.04% |
| 1995-12-31 | CN¥82.53 Million | -- |